Empowered Funds LLC Invests $1.50 Million in USANA Health Sciences, Inc. $USNA

Key Points

• Empowered Funds LLC acquired 70,253 USANA shares worth approximately $1.5 million, representing about 0.38% of the company. Institutional investors collectively own 54.25% of USANA’s stock.
• Analyst sentiment is negative: Zacks Research downgraded the stock to “strong sell,” Wall Street Zen lowered it to “hold,” and the overall MarketBeat rating is “Sell.”
• USANA reported quarterly revenue of $223.27 million and a loss of $0.07 per share, missing estimates of $235 million in revenue and $0.43 EPS. The stock opened at $14.44, near its one-year low of $12.57 and well below its 52-week high of $32.29.

Empowered Funds LLC purchased a new stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 70,253 shares of the company's stock, valued at approximately $1,500,000. Empowered Funds LLC owned approximately 0.38% of USANA Health Sciences at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in shares of USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company's stock valued at $244,000 after acquiring an additional 542 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after buying an additional 646 shares during the last quarter. Intech Investment Management LLC lifted its position in USANA Health Sciences by 13.5% during the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company's stock worth $213,000 after acquiring an additional 918 shares during the period. National Bank of Canada FI grew its position in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company's stock valued at $53,000 after buying an additional 1,201 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company's stock valued at $106,000 after buying an additional 1,327 shares during the period. 54.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on USNA. Zacks Research cut shares of USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 6th. Wall Street Zen lowered shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of "Sell".

USANA Health Sciences Stock Performance

NYSE:USNA opened at $14.44 on Friday. The stock has a fifty day moving average price of $18.43 and a two-hundred day moving average price of $18.60. The stock has a market capitalization of $266.85 million, a price-to-earnings ratio of -11.93, a PEG ratio of 1.60 and a beta of 0.68. USANA Health Sciences, Inc. has a 1 year low of $12.57 and a 1 year high of $32.29.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.The company had revenue of $223.27 million for the quarter, compared to analysts' expectations of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, analysts predict that USANA Health Sciences, Inc. will post 0.76 EPS for the current year.

Insider Activity at USANA Health Sciences

In related news, insider Brent Neidig sold 5,002 shares of the business's stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.82% of the stock is owned by company insiders.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source